The University of Nottingham

FALCON Trial: Fulvestrant Shows No Overall Survival Advantage vs. Anastrozole in HR+ Advanced Breast Cancer

4 months ago

• The phase 3 FALCON trial's final overall survival (OS) analysis showed no significant difference between fulvestrant and anastrozole in endocrine therapy-naive, HR-positive advanced breast cancer. • Median OS was 44.8 months for fulvestrant versus 42.7 months for anastrozole (HR, 0.97; P = .76), with a median follow-up of 37.1 months. • A trend toward improved survival with fulvestrant was observed in patients with nonvisceral disease (median OS 65.2 months vs 47.8 months; HR, 0.85). • Post-hoc analysis revealed greater OS improvement with fulvestrant in nonvisceral vs. visceral disease subgroups compared to anastrozole.

QuEra Computing-Powered Projects Advance in Wellcome Leap's Quantum for Bio Challenge

6 months ago

• Three research projects involving QuEra Computing have progressed to Phase Two of the Wellcome Leap's Quantum for Bio Challenge, focusing on healthcare revolution through quantum computing. • These projects target quantum-enhanced drug discovery for myotonic dystrophy, scalable quantum simulation for virtual screening, and quantum chemistry techniques for Alzheimer's and Parkinson's-related proteins. • QuEra's neutral-atom quantum computers, accessible via public cloud, provide advanced processing capabilities, supporting large-scale simulations and paving the way for quantum breakthroughs in healthcare.